Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMT101 in healthy volunteers
NCT03133130Phase 1Completed
- Sponsor
- Hugel
- Start
- Jul 2017
- Primary completion
- Feb 2018
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Hypertrophic Scar (HS) comparing BMT101 with Placebo (2 arms). Primary endpoint: Severity and frequency of reported adverse events, clinically-relevant changes in physical exams or laboratory testing at 14 days. Started Jul 2017; status: completed.
02
Drugs
OLX10010
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT03133130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03133130.